Roberto A Wharton, PTA | |
905 Main St, Lisbon, ND 58054-4334 | |
(701) 683-6458 | |
Not Available |
Full Name | Roberto A Wharton |
---|---|
Gender | Male |
Speciality | Physical Medicine & Rehabilitation |
Location | 905 Main St, Lisbon, North Dakota |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1467918391 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208100000X | Physical Medicine & Rehabilitation | 1229A (North Dakota) | Primary |
Mailing Address | Practice Location Address |
---|---|
Roberto A Wharton, PTA 905 Main St, Lisbon, ND 58054-4334 Ph: (701) 683-6458 | Roberto A Wharton, PTA 905 Main St, Lisbon, ND 58054-4334 Ph: (701) 683-6458 |
News Archive
Today, The Endocrine Society released "Evaluation, Treatment, and Prevention of Vitamin D Deficiency: An Endocrine Society Clinical Practice Guideline." The clinical practice guideline (CPG) is published in the July 2011 issue of the Journal of Clinical Endocrinology & Metabolism (JCEM), a publication of The Endocrine Society.
Working alongside research groups from Heidelberg, researchers from Charité - Universitätsmedizin Berlin have elucidated the novel disease processes involved in the development of pulmonary fibrosis.
Today, the magnets used in nuclear magnetic resonance (NMR) and medical magnetic resonance imaging (MRI) represent the primary commercial applications of superconductivity. NMR, used mainly in the chemical and pharmaceutical industry, allows discovering new molecules, studying the structure of proteins or analyzing food content. It is essential for drug development or the quality control of chemical compounds.
Researchers at the University of Malaga have analysed the presence of voice disorders in male and female teachers, in order to obtain a representative statistic: 62.7% of the Early Childhood and Primary Education teaching body suffer from these complaints on a daily or weekly basis.
Merck & Co., Inc. and the HIV Vaccine Trials Network (HVTN) today announced that study volunteers in the STEP study of Merck's HIV vaccine (V520) will be told whether they received vaccine or placebo, and all study volunteers will be encouraged to continue to return to their study sites on a regular basis for ongoing risk reduction counseling and study-related tests.
› Verified 6 days ago